Rocket Pharmaceuticals

ISIN US77313F1066

 | 

WKN A2JA9Q

Market cap (in EUR)
360 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 360 m
EPS, EUR -2.04
P/B ratio 1.3
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR -
Net income, EUR -239 m
Profit margin -

What ETF is Rocket Pharmaceuticals in?

There are 2 ETFs which contain Rocket Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Rocket Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.03%
Equity
United States
Health Care
Biotech
45
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.00%
Equity
United States
Small Cap
185
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.